Predicting risk of secondary progression in multiple sclerosis: A nomogram.


Journal

Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185

Informations de publication

Date de publication:
07 2019
Historique:
pubmed: 19 6 2018
medline: 20 3 2020
entrez: 19 6 2018
Statut: ppublish

Résumé

We aimed at designing a nomogram, a prediction tool, to predict the individual's risk of conversion to secondary progressive multiple sclerosis (SPMS) at the time of multiple sclerosis (MS) onset. One derivation and three validation cohorts were established. The derivation cohort included 8825 relapsing-onset MS patients in Sweden. A nomogram was built based on a survival model with the best statistical fit and prediction accuracy. The nomogram was validated using data from 3967 patients in the British Columbia cohort, 176 patients in the ACROSS and 2355 patients in FREEDOMS/FREEDOMS II extension studies. Sex, calendar year of birth, first-recorded Expanded Disability Status Scale (EDSS) score, age at the first EDSS and age at disease onset showed significant predictive ability to estimate the risk of SPMS conversion at 10, 15 and 20 years. The nomogram reached 84% (95% confidence intervals (CIs): 83-85) internal and 77% (95% CI: 76-78), 77% (95% CI: 70-85) and 87% (95% CI: 84-89) external accuracy. The SPMS nomogram represents a much-needed complementary tool designed to assist in decision-making and patient counselling in the early phase of MS. The SPMS nomogram may improve outcomes by prompting timely and more efficacious treatment for those with a worse prognosis.

Identifiants

pubmed: 29911467
doi: 10.1177/1352458518783667
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1102-1112

Auteurs

Ali Manouchehrinia (A)

Department of Clinical Neuroscience (CNS), Karolinska Institutet, Stockholm, Sweden.

Feng Zhu (F)

Division of Neurology, UBC Hospital, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada.

Daniela Piani-Meier (D)

Novartis Pharma AG, Basel, Switzerland.

Markus Lange (M)

Novartis Pharma AG, Basel, Switzerland.

Diego G Silva (DG)

Novartis Pharma AG, Basel, Switzerland.

Robert Carruthers (R)

Division of Neurology, UBC Hospital, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada.

Anna Glaser (A)

Department of Clinical Neuroscience (CNS), Karolinska Institutet, Stockholm, Sweden.

Elaine Kingwell (E)

Division of Neurology, UBC Hospital, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada.

Helen Tremlett (H)

Division of Neurology, UBC Hospital, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada.

Jan Hillert (J)

Department of Clinical Neuroscience (CNS), Karolinska Institutet, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH